USA    |    Global :  English    中文    Español    |    MAP
  Login    |      Shopping Cart
About CytoTest
  Company Overview
  Management Team
  News & Events
  Business Opportunities
  Job Opportunity
  Contact CytoTest
  Management Team

 Chief Executive Officer - Matthew Lee

I Graduated from Virginia Tech with a B.S. in Biochemistry and nutrition and then pursed my doctoral study of neural regeneration of the PNS at Medical College of Virginia. After which I did my post-doctoral research in CNS regeneration and stem cell identification. In 2000, I returned to Taiwan and worked at the Center for Drug Evaluation in the biologics section. After two years at the regulatory agency, I then moved on to the biotech venture capital investment arena where I focused primarily on new drug development and stem cell related investments. After six years in the investment world, I then moved into the Medical Affairs at Bristol-Myers Squibb and was in charge of few new oncology drug developments and the eventual launch in the Asia Pacific. After two years, I participated in the start-up of a couple of successful biotech start-ups in Taiwan which went on to IPO in TASDAQ which included OBI Pharma (TPEX, 4174) and CrownBio (TPEX, 6554). I also assisted many biotech companies in Asia in different capacities, many of which went onto IPO or were merged. Then in 2020, I joined Cytotest Inc. at the invitation of Chairman Vinsen Hsiao to help restructure the company and transition into a modern genetic company in the era of personalized medicine.

 Chief Scientific Advisor - Reinhard Ebner 

Dr. Reinhard Ebner has been a research manager and senior investigator for over 30 years. He has wide scientific, technical and strategic experience, in both academic and corporate settings, with broad knowledge of modern biology and the pharmaceutical and bio-technology industry, and a recent focus in contemporary oncology and translational medicine, and a documented record of discoveries leading to novel therapies in the clinic and on the market. 

He has extensive hands-on experience with, and documented record of achievements in, target and marker discovery, assay development, high-throughput screening, signal transduction and pathway delineation, lead optimization and development, and proven expertise in solving complex questions in molecular and cell biology, particularly as they relate to disease mechanism and drug discovery. 

Having served as a research manager and senior investigator in both academic and corporate settings, Dr. Reinhard Ebner has extensive scientific, technical and strategy experience, combined with a broad knowledge of modern biology and the biomedical and biotechnology industry, with a recent focus in contemporary oncology, translational medicine and molecular diagnostics.
He received his undergraduate degree in Biology from the University of Regensburg and his doctorate in Microbiology and Genetics from the University of Osnabrück, Germany, where he then served on the faculty of the Genetics department.
In 1989, Dr. Ebner was awarded a research fellowship to work as a visiting scientific specialist at Genentech, Inc. in San Francisco. There, he identified and cloned the long elusive first type I TGF-ß receptor. He was first to show TGFß-induced epithelial-mesenchymal-transitions (EMTs) in cells in culture and, in the years following, made a series of substantial contributions to the fields of cytokine biology, receptor-ligand interactions and intracellular trafficking, cell differentiation, early development and tissue repair, first at Genentech and then at the University of California, San Francisco and at Stanford University Medical School.
After moving to Human Genome Sciences in 1995, Dr. Ebner became one of the most productive novel gene finders there and the inventor of all the HGS targets now in clinical trials and discovered many other important proteins around which HGS established pre-clinical and clinical development programs, including such molecules as DR4, the first and long sought after receptor for the cytotoxic ligand TRAIL, as well as LIGHT, IL-17B and its receptor, BlyS and TR6. In 2000, he joined Avalon Pharmaceuticals – hired as the first scientist following the company founders, where he was instrumental in the initiation of intramural and external research programs and contributed to corporate and scientific infrastructure development, working predominantly in the fields of chemical genomics, cancer research, data mining and HTS assay development. He also coordinated the company’s therapeutic antibody target discovery alliances and has a long-standing interest in alternative and novel drug discovery paradigms and development strategies.
Dr. Ebner is a frequently invited plenary speaker at national and international conferences and member of several scientific advisory panels and has served on state and national study sections. He has authored nearly 100 original research publications, with several thousand citations by others. He is a recipient of grant and manuscript peer review service awards and society memberships, an ad hoc reviewer and editor for scientific journals, has over 50 issued US patents and is the primary inventor on more than 800 patent applications world wide. Several of his discoveries have led to new therapeutics now in the clinic or on the market.
Dr. Ebner has been involved with the National Cancer Institute for many years, and is currently a research adviser in its cancer genomics section. He also is a consultant to various biotech companies, and serves as the CSO of CytoTest Inc., a provider of innovative molecular diagnostic solutions.

 Scientific Advisor - Michael Koehler 


Dr. Michael Koehler is a proven expert in the field of molecular cytogenetics with more than 25 years of professional experience in both academic as well as in industry settings.  During his academic career he was among the first scientists introducing and utilizing Fluorescence in Situ Hybridization (FISH) with genomic DNA probes in Europe and after leaving university he also became a known expert in state of the art cytogenetic imaging techniques, software and systems.
Dr. Koehler graduated with a Diploma degree in Molecular Genetics and Human Biology from the Human Genetics Institute, University of Heidelberg, Germany where he also received his Ph.D. in 1994. After working as a scientist between 1994 and 1997 in the laboratory of Prof. Michael Schmid (Human Genetics Institute, Wuerzburg University) – another pioneering research group in molecular cytogenetics – he joined the lab of Dr. Thomas Ried at the National Human Genome Research Institute (NHGRI/NIH) in the USA as a visiting scientist. At that time he made contact to Applied Spectral Imaging (ASI), the company which invented together with Dr. Ried`s group the famous multicolor Spectral Karyotyping (SKY®) application which revolutionized cytogenetic diagnosis and research. After his return to Germany Dr. Koehler joined ASI as Technical & Scientific Manager and headed the company’s European office for many years. Initially responsible for sales in Germany and technical support of ASI customers and distributors throughout Europe the demand for his expertise quickly increased and soon his activities were extended worldwide, providing customer support, giving lectures on international conferences, and supervising workshops in countries like China, India, Russia, Canada and USA as well as in multiple South-East-Asian, Middle Eastern and South American countries.
Dr. Koehler is author and co-author of more than 40 peer reviewed scientific publications and several industrial articles and application notes and has served as a reviewer for several scientific magazines in the field of molecular cytogenetics.

 VP/Sales Manager – Tomasz Czerski 


Mr. Tomasz Czerski is a effective, entrepreneurial, self- motivated commercial leader with almost 20 years solid track record of achievement in medical devices area, primarily in molecular diagnostics business, strongly focused on performance at top and bottom line. Creative, transformational business leader that  manages team through empowerment and development, able to accommodate to difficult business conditions and to make difficult decisions. Experienced in talent attraction and development.
Mr,Thomasz developed and led strong multifunctional international commercial organizations. Built Abbott Central Eastern Europe  and Middle East Molecular Dx business from the establishing of Division to a $33MLN in sales.
Developed strategy and organization for key Emerging Markets such as Russia, Ukraine, Turkey, Poland. Before transition to other division, initiated breakthrough projects in Kazakhstan, Azerbaijan and Belarus.
Established local manufacturing of Real Time HIV viral load tests in Russia. 
Built strong network of distributors, established key collaborations with NGOs and government organizations in key Central Eastern Europe and Middle East markets.  Experienced in collaboration / co-promotion with Pharma Industry (Roche, Novartis, Pfizer) as well and Abbott Pharma.





CytoTest Inc.  |  9430 Key West Avenue, Suite 210, Rockville, MD 20850, USA
Tel:1-855-CYTOTEST  |  +1-202-688-1188  |

© 2013-2019 CytoTest Inc. All Rights Reserved.
Website Design | Youhome